A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 270,950 shares of IBRX stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
270,950
Previous 270,950 -0.0%
Holding current value
$1.22 Million
Previous $1.71 Million 41.3%
% of portfolio
0.0%
Previous 0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$3.23 - $6.17 $875,168 - $1.67 Million
270,950 New
270,950 $1.46 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.